Navigation Links
Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board
Date:8/22/2007

DANBURY, Conn., Aug. 22 /PRNewswire-FirstCall/ -- Biodel, Inc. (Nasdaq: BIOD) today announced the addition of Ralf Rosskamp, M.D., to its Scientific Advisory Board (SAB).

Dr. Rosskamp was previously the Executive Vice President of Research and Development at Kos Pharmaceuticals, where he managed all research and development activities until Kos was acquired by Abbott Laboratories. Dr. Rosskamp's accomplishments at Kos include building an integrated research and development organization, globally expanding Kos's clinical research organization and assisting in the approval of four supplemental new drug applications.

"We are extremely honored to have Dr. Rosskamp join our SAB," said Dr. Solomon Steiner, CEO and Chairman of Biodel. "Dr. Rosskamp played an integral role in bringing insulin analogs to the market. His wealth of knowledge and clinical experience in the field of endocrinology will significantly contribute to the development of VIAject(TM), VIAtab(TM) and our two osteoporosis product candidates."

"I am delighted to join Biodel's SAB, especially at such an exciting time for the Company," said Dr. Rosskamp. "Biodel has created an innovative, injectable human insulin for diabetics and has made great progress in the clinical development of VIAject(TM). I look forward to collaborating with the Biodel team in their efforts to bring safer and more effective treatments to the diabetic patient population."

Prior to joining Kos, Dr. Rosskamp held prominent positions for thirteen years at Aventis Pharmaceuticals, a lead-developer of endocrinology products. At Aventis, Dr. Rosskamp was responsible for achieving FDA/EMEA approval of Lantus(R), the best-selling basal insulin analog and coordinating the clinical trials for Apidra(R), a rapid-acting insulin analog. In addition, Dr. Rosskamp managed the approval process for Actonel(R) Once-a-Week, which prevents and treats post-menopausal osteoporosis, and aided in completing the Phase III study
'/>"/>

SOURCE Biodel, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years of ... restoring hope an quality of life and contributing to ... of the innovative cellular biomedicines research that made Topricin® ... , The company was founded in 1994 in a ... of research, and Topricin inventor), Aurora Paradise (COO) and ...
(Date:9/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/22/2014)... (Nasdaq: NEOG ) announced today that net ... year, which ended Aug. 31, was $8,883,000 — a ... the first quarter of last year. Adjusted for a ... share in the current quarter were $0.24, compared to ... increased 15% to $67,599,000, from the previous year,s first ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... following Webcast:, What: Transgenomic Inc. Fourth Quarter ... Conference Call, When: Thursday, February 28, 2008 ... How: Live over the Internet -- Simply log ... address above., To access the call via telephone, call ...
... 28 Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) announced today that it ... March,6, 2008, before the U.S. financial markets open. Management will provide a,Company ... 6, 2008, at 9:00 a.m. EST., Investors and ... ...
... New England Journal of Medicine, led by researchers at ... University of Massachusetts Medical School (UMMS), indicates a declining ... the first demonstration of a link between two independent ... has offered universal newborn screening to detect cystic fibrosis ...
Cached Biology Technology:Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008 2Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:9/19/2014)... resource unveiled today by researchers from several Harvard ... provides both experienced and aspiring researchers with the ... operate robots made from soft, flexible materials. , ... cutters, and other advances in manufacturing technology, soft ... Using principles drawn from conventional rigid robot design, ...
(Date:9/19/2014)... of Oklahoma biology professor will study multifunctional and ... movements with a National Science Foundation grant in ... , Ari Berkowitz, professor in the Department of ... focus on the differences between the multifunctional and ... neurotransmitters they use and what connections they make. ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... This press release is available in ... scientists working with the University of Illinois at Urbana-Champaign ... soybean yields by an average 23 percent. Randy ... Research Service Soybean/Maize Germplasm, Pathology, and Genetics Research Unit ...
... DC, Aug. 22The Martin Luther King, Jr. Health Equity ... Multicultural and Minority Medicine (IAMMM), opens today as the ... opens to the public on the National Mall. Both ... focusing tightly on the health status of minorities and ...
... a five-year grant is considered a long-term grant, Alan R. Templeton, ... University in St. Louis, has managed to follow some of the ... Early in his career he studied parthenogenesis, or virgin birth, in ... Hawaii. "Drosophilia have fast generation times," he says, "but I ...
Cached Biology News:Breeding ozone-tolerant crops 2MLK, Jr. Health Equity Summit opens as memorial to Dr. King is unveiled in DC 2Restoration as science: case of the collared lizard 2Restoration as science: case of the collared lizard 3Restoration as science: case of the collared lizard 4Restoration as science: case of the collared lizard 5Restoration as science: case of the collared lizard 6Restoration as science: case of the collared lizard 7Restoration as science: case of the collared lizard 8Restoration as science: case of the collared lizard 9
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: